{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:47:18Z","timestamp":1777434438259,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s11926-015-0543-y","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T03:24:30Z","timestamp":1443065070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunological Biomarkers in Dermatomyositis"],"prefix":"10.1007","volume":"17","author":[{"given":"Jeannette M.","family":"Olazagasti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Niewold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,24]]},"reference":[{"key":"543_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.rdc.2011.01.002","volume":"37","author":"K Nagaraju","year":"2011","unstructured":"Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin N Am. 2011;37:159\u201371. v.","journal-title":"Rheum Dis Clin N Am"},{"key":"543_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.7326\/0003-4819-111-2-143","volume":"111","author":"PH Plotz","year":"1989","unstructured":"Plotz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989;111:143\u201357.","journal-title":"Ann Intern Med"},{"key":"543_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1995.tb32309.x","volume":"762","author":"PB Sehgal","year":"1995","unstructured":"Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6-type cytokines. Ann N Y Acad Sci. 1995;762:1\u201314.","journal-title":"Ann N Y Acad Sci"},{"key":"543_CR4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","volume":"40","author":"I Lundberg","year":"1997","unstructured":"Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865\u201374.","journal-title":"Arthritis Rheum"},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60:3436\u201346.","journal-title":"Arthritis Rheum"},{"key":"543_CR6","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64:4078\u201386. IL-6 expression in peripheral blood of patients with DM was assessed by performing multiplexed immunoassays. Serum IL-6 levels were significantly elevated in DM patients. Furthermore, the serum levels of IL-6 correlated with disease activity.","journal-title":"Arthritis Rheum"},{"key":"543_CR7","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014;53:2196\u2013203. Serum levels of IL-6 were evaluated in DM patients with interstitial lung disease (ILD) and compared them to the non-ILD subset. IL-6 levels were significantly higher in the ILD subset than the non-ILD subset.","journal-title":"Rheumatology"},{"key":"543_CR8","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.4049\/jimmunol.164.12.6593","volume":"164","author":"T Sugiura","year":"2000","unstructured":"Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000;164:6593\u2013600.","journal-title":"J Immunol"},{"key":"543_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00032-8","volume":"137","author":"G Chevrel","year":"2003","unstructured":"Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003;137:125\u201333.","journal-title":"J Neuroimmunol"},{"key":"543_CR10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","volume":"40","author":"H Shen","year":"2011","unstructured":"Shen H, Xia L, Lu J, Xiao W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol. 2011;40:217\u201320.","journal-title":"Scand J Rheumatol"},{"key":"543_CR11","first-page":"428","volume":"31","author":"L Yuan","year":"2013","unstructured":"Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013;31:428\u201332.","journal-title":"Clin Exp Rheumatol"},{"key":"543_CR12","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","volume":"66","author":"F Bellutti Enders","year":"2014","unstructured":"Bellutti Enders F, van Wijk F, Scholman R, Hofer M, Prakken BJ, van Royen-Kerkhof A, et al. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheum. 2014;66:2281\u20139. Serum levels of CXCL10 were increased in a juvenile DM cohort compared with the levels in healthy controls. Moreover, levels of CXCL10 were strongly correlated with the global VAS scores.","journal-title":"Arthritis Rheum"},{"key":"543_CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejcb.2011.09.011","volume":"91","author":"C Crescioli","year":"2012","unstructured":"Crescioli C, Sottili M, Bonini P, Cosmi L, Chiarugi P, Romagnani P, et al. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol. 2012;91:139\u201349.","journal-title":"Eur J Cell Biol"},{"key":"543_CR14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664\u201378.","journal-title":"Ann Neurol"},{"key":"543_CR15","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e31821f440a","volume":"76","author":"C Cappelletti","year":"2011","unstructured":"Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology. 2011;76:2079\u201388.","journal-title":"Neurology"},{"key":"543_CR16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065362","volume":"8","author":"S Franzi","year":"2013","unstructured":"Franzi S, Salajegheh M, Nazareno R, Greenberg SA. Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15. PLoS One. 2013;8, e65362.","journal-title":"PLoS One"},{"key":"543_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","volume":"67","author":"M Salajegheh","year":"2010","unstructured":"Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010;67:53\u201363.","journal-title":"Ann Neurol"},{"key":"543_CR18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60:1815\u201324.","journal-title":"Arthritis Rheum"},{"key":"543_CR19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670\u20137.","journal-title":"Ann Rheum Dis"},{"key":"543_CR20","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1542\/peds.2010-3022","volume":"127","author":"TB Niewold","year":"2011","unstructured":"Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. 2011;127:e1239\u20131246.","journal-title":"Pediatrics"},{"key":"543_CR21","doi-asserted-by":"crossref","unstructured":"Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM: Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr 2010.","DOI":"10.1016\/j.jpeds.2010.04.034"},{"key":"543_CR22","doi-asserted-by":"crossref","unstructured":"Balboni I, Niewold TB, Morgan G, Limb C, Eloranta ML, Ronnblom L, Utz PJ, Pachman LM: Detection of anti-Ro, La, Smith and RNP autoantibodies by autoantigen microarray analysis and interferon-alpha induction in juvenile dermatomyositis. Arthritis and rheumatism 2013. High serum type I IFN in JDM patients was shown to be correlated with autoantibodies against RNA-binding proteins, explaining some of the heterogeneity between patients in circulating type I IFN.","DOI":"10.1002\/art.38038"},{"key":"543_CR23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70:831\u20136.","journal-title":"Ann Rheum Dis"},{"key":"543_CR24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13:59\u201368.","journal-title":"Mol Med"},{"key":"543_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6\u201313.","journal-title":"Autoimmun Rev"},{"key":"543_CR26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59:159\u201363.","journal-title":"Eur Neurol"},{"key":"543_CR27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1378\/chest.108.2.311","volume":"108","author":"J Kobayashi","year":"1995","unstructured":"Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108:311\u20135.","journal-title":"Chest"},{"key":"543_CR28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mpd.2001.110324","volume":"138","author":"I Kobayashi","year":"2001","unstructured":"Kobayashi I, Ono S, Kawamura N, Okano M, Miyazawa K, Shibuya H, et al. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis. J Pediatr. 2001;138:274\u20136.","journal-title":"J Pediatr"},{"key":"543_CR29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/rheumatology\/39.6.632","volume":"39","author":"M Kubo","year":"2000","unstructured":"Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology. 2000;39:632\u20136.","journal-title":"Rheumatology"},{"key":"543_CR30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkova","year":"2009","unstructured":"Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68:836\u201343.","journal-title":"Ann Rheum Dis"},{"key":"543_CR31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/bmm.13.124","volume":"8","author":"QL Peng","year":"2014","unstructured":"Peng QL, Shu XM, Wang DX, Wang Y, Lu X, Wang GC. B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med. 2014;8:395\u2013403.","journal-title":"Biomark Med"},{"key":"543_CR32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3899\/jrheum.120555","volume":"40","author":"CM Lopez De Padilla","year":"2013","unstructured":"Lopez De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS, et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheum. 2013;40:294\u2013302. They examined mRNA-expression levels of BAFF and their correlations with disease activity and found that BAFF mRNA levels of peripheral blood mononuclear cells correlated positively with disease activity measures in DM patients.","journal-title":"J Rheum"},{"key":"543_CR33","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar3836","volume":"14","author":"M Filkova","year":"2012","unstructured":"Filkova M, Hulejova H, Kuncova K, Plestilova L, Cerezo LA, Mann H, et al. Resistin in idiopathic inflammatory myopathies. Arthritis Res Ther. 2012;14:R111.","journal-title":"Arthritis Res Ther"},{"key":"543_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12950-015-0075-2","volume":"12","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Hein M, Crowson CS, de Padilla CL, Peterson E, Baechler EC, et al. Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. J Inflamm. 2015;12:29.","journal-title":"J Inflamm"},{"key":"543_CR35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ajpath.2013.06.003","volume":"183","author":"M Freret","year":"2013","unstructured":"Freret M, Drouot L, Obry A, Ahmed-Lacheheb S, Dauly C, Adriouch S, et al. Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. Am J Pathol. 2013;183:893\u2013904.","journal-title":"Am J Pathol"},{"key":"543_CR36","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","volume":"52","author":"K Nagaraju","year":"2005","unstructured":"Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005;52:1824\u201335.","journal-title":"Arthritis Rheum"},{"key":"543_CR37","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1073\/pnas.97.16.9209","volume":"97","author":"K Nagaraju","year":"2000","unstructured":"Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A. 2000;97:9209\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"543_CR38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0028-3886.43457","volume":"56","author":"C Sundaram","year":"2008","unstructured":"Sundaram C, Uppin MS, Meena AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008;56:363\u20137.","journal-title":"Neurol India"},{"key":"543_CR39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jclinpath-2011-200138","volume":"65","author":"R Salaroli","year":"2012","unstructured":"Salaroli R, Baldin E, Papa V, Rinaldi R, Tarantino L, De Giorgi LB, et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Pathol. 2012;65:14\u20139.","journal-title":"J Clin Pathol"},{"key":"543_CR40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","volume":"17","author":"M Needham","year":"2007","unstructured":"Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17:194\u2013200.","journal-title":"Neuromuscul Disord"},{"key":"543_CR41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","volume":"24","author":"PM Rodriguez Cruz","year":"2014","unstructured":"Rodriguez Cruz PM, Luo YB, Miller J, Junckerstorff RC, Mastaglia FL, Fabian V. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord : NMD. 2014;24:1025\u201335.","journal-title":"Neuromuscul Disord : NMD"},{"key":"543_CR42","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1016\/j.febslet.2011.04.028","volume":"585","author":"KC Santegoets","year":"2011","unstructured":"Santegoets KC, van Bon L, van den Berg WB, Wenink MH, Radstake TR. Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs? FEBS Lett. 2011;585:3660\u20136.","journal-title":"FEBS Lett"},{"key":"543_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-009-1316-7","volume":"29","author":"GT Kim","year":"2010","unstructured":"Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol. 2010;29:273\u20139.","journal-title":"Clin Rheumatol"},{"key":"543_CR44","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/NEN.0b013e31826bf7f3","volume":"71","author":"A Brunn","year":"2012","unstructured":"Brunn A, Zornbach K, Hans VH, Haupt WF, Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 2012;71:855\u201367.","journal-title":"J Neuropathol Exp Neurol"},{"key":"543_CR45","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.27465","volume":"62","author":"A Tournadre","year":"2010","unstructured":"Tournadre A, Lenief V, Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010;62:2144\u201351.","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-015-0543-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0543-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T09:49:42Z","timestamp":1718099382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-015-0543-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,24]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s11926-015-0543-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,24]]},"article-number":"68"}}